Diagnosis and treatment of MYH9-RD in an Australasian cohort with thrombocytopenia
暂无分享,去创建一个
M. Morel-Kopp | C. Ward | B. Kile | L. Chew | S. Kunishima | W. Stevenson | R. Bird | P. Ockelford | R. Burt | M. Latimer | P. Tan | K. Fixter | D. Rabbolini | B. Valecha | S. Gabrielli | Qiang Chen | Yenna Chun | K. Radhakrishnan
[1] A. Savoia,et al. MYH9 gene mutations associated with bleeding , 2017, Platelets.
[2] S. Kojima,et al. Efficacy of neutrophil non-muscle myosin heavy chain-IIA immunofluorescence analysis in determining the pathogenicity of MYH9 variants , 2017, Annals of Hematology.
[3] S. Ruhoy,et al. Macrothrombocytopenia With Döhle Body-Like Granulocyte Inclusions: A Case Report of May-Hegglin Anomaly in a 33-Year-Old White Woman With an Update on the Molecular Findings of MYH9-Related Disease. , 2016, Laboratory medicine.
[4] Y. Lee,et al. New synergistic efficacy of combination of romiplostim and steroid in refractory immune thrombocytopenia patients , 2016, The Korean journal of internal medicine.
[5] A. Pecci,et al. Diagnosis and treatment of inherited thrombocytopenias , 2016, Clinical genetics.
[6] J. Wasser,et al. Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim , 2015, International Journal of Hematology.
[7] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[8] C. Gachet,et al. Diagnosis of suspected inherited platelet function disorders: results of a worldwide survey , 2014, Journal of thrombosis and haemostasis : JTH.
[9] P. Noris,et al. Platelet diameters in inherited thrombocytopenias: analysis of 376 patients with all known disorders. , 2014, Blood.
[10] M. Ballmaier,et al. MYH9‐Related Disease: A Novel Prognostic Model to Predict the Clinical Evolution of the Disease Based on Genotype–Phenotype Correlations , 2014, Human mutation.
[11] S. Miyano,et al. Normal neutrophil myosin IIA localization in an immunofluorescence analysis can rule out MYH9 disorders , 2013, Journal of thrombosis and haemostasis : JTH.
[12] K. Gomez,et al. May–Hegglin anomaly and pregnancy: a systematic review , 2013, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[13] A. Savoia,et al. Inherited thrombocytopenias frequently diagnosed in adults , 2013, Journal of thrombosis and haemostasis : JTH.
[14] J. Bussel,et al. Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy , 2013, British journal of haematology.
[15] P. Noris,et al. Platelet size for distinguishing between inherited thrombocytopenias and immune thrombocytopenia: a multicentric, real life study , 2013, British journal of haematology.
[16] J. Bussel,et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. , 2013, Blood.
[17] A. Tantawy,et al. Romiplostim therapy in children with unresponsive chronic immune thrombocytopenia , 2012, Platelets.
[18] C. Balduini,et al. Short-term eltrombopag for surgical preparation of a patient with inherited thrombocytopenia deriving from MYH9 mutation , 2012, Thrombosis and Haemostasis.
[19] A. Greinacher,et al. A patient with Fechtner syndrome successfully treated with romiplostim , 2012, Thrombosis and Haemostasis.
[20] A. Savoia,et al. Recent advances in the understanding and management of MYH9‐related inherited thrombocytopenias , 2011, British journal of haematology.
[21] M. Crowther,et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. , 2011, Blood.
[22] K. Moon,et al. Renal manifestations of patients with MYH9-related disorders , 2011, Pediatric Nephrology.
[23] P. Noris,et al. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. , 2010, Blood.
[24] A. Greinacher,et al. MYH-9 Related Platelet Disorders: Strategies for Management and Diagnosis , 2010, Transfusion Medicine and Hemotherapy.
[25] Jana Marie Schwarz,et al. MutationTaster evaluates disease-causing potential of sequence alterations , 2010, Nature Methods.
[26] P. Bork,et al. A method and server for predicting damaging missense mutations , 2010, Nature Methods.
[27] P. Noris,et al. Heavy chain myosin 9-related disease (MYH9-RD): Neutrophil inclusions of myosin-9 as a pathognomonic sign of the disorder , 2010, Thrombosis and Haemostasis.
[28] P. Noris,et al. Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia , 2009, Journal of thrombosis and haemostasis : JTH.
[29] A. Greinacher,et al. MYH9-related platelet disorders. , 2009, Seminars in thrombosis and hemostasis.
[30] J. Bussel,et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.
[31] P. Noris,et al. Position of nonmuscle myosin heavy chain IIA (NMMHC‐IIA) mutations predicts the natural history of MYH9‐related disease , 2008, Human mutation.
[32] J. George,et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial , 2008, The Lancet.
[33] J. Bussel,et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. , 2007, The New England journal of medicine.
[34] T. Eddinger,et al. Myosin II isoforms in smooth muscle: heterogeneity and function. , 2007, American journal of physiology. Cell physiology.
[35] H. Amagai,et al. Identification of inherited macrothrombocytopenias based on mean platelet volume among patients diagnosed with idiopathic thrombocytopenia. , 2005, Thrombosis research.
[36] B. Bader-Meunier,et al. Misdiagnosis of Chronic Thrombocytopenia in Childhood , 2003, Journal of pediatric hematology/oncology.
[37] R. Ravazzolo,et al. MYH9-Related Disease: May-Hegglin Anomaly, Sebastian Syndrome, Fechtner Syndrome, and Epstein Syndrome Are not Distinct Entities but Represent a Variable Expression of a Single Illness , 2003, Medicine.
[38] Toshihiro Tanaka,et al. Mutations in the NMMHC-A gene cause autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly/Sebastian syndrome). , 2001, Blood.
[39] T. Ortel,et al. Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly , 2000, Nature Genetics.
[40] U Magrini,et al. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium. , 2000, Nature genetics.
[41] M. Margaglione,et al. Compound Heterozygosity (554-589 del, C515-T Transition) in the Platelet Glycoprotein Ibα Gene in a Patient with a Severe Bleeding Tendency , 1999, Thrombosis and Haemostasis.
[42] S. Henikoff,et al. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.
[43] M. Marcelli,et al. Design and methods , 2016 .
[44] H. Saito,et al. Immunofluorescence Analysis of Neutrophil Nonmuscle Myosin Heavy Chain-A in MYH9 Disorders: Association of Subcellular Localization with MYH9 Mutations , 2003, Laboratory Investigation.
[45] The May-HegglinFechtner Syndrome Consortium,et al. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes , 2000, Nature Genetics.
[46] T Hodge,et al. A myosin family tree. , 2000, Journal of cell science.